Edotreotide

Edotreotide

IUPAC name 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Identifiers
CAS number	204318-14-9^N
PubChem	158782
UNII	U194AS08HZ^Y
Jmol-3D images	Image 1
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)CN6CCN(CCN(CCN(CC6)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CO)C(C)O)O
InChI InChI=1S/C65H92N14O18S2/c1-39(81)51(36-80)72-64(96)53-38-99-98-37-52(73-60(92)48(28-41-10-4-3-5-11-41)68-54(84)32-76-20-22-77(33-55(85)86)24-26-79(35-57(89)90)27-25-78(23-21-76)34-56(87)88)63(95)70-49(29-42-15-17-44(83)18-16-42)61(93)71-50(30-43-31-67-46-13-7-6-12-45(43)46)62(94)69-47(14-8-9-19-66)59(91)75-58(40(2)82)65(97)74-53/h3-7,10-13,15-18,31,39-40,47-53,58,67,80-83H,8-9,14,19-30,32-38,66H2,1-2H3,(H,68,84)(H,69,94)(H,70,95)(H,71,93)(H,72,96)(H,73,92)(H,74,97)(H,75,91)(H,85,86)(H,87,88)(H,89,90)/t39-,40-,47+,48-,49+,50-,51-,52+,53+,58+/m1/s1 Key: RZHKDBRREKOZEW-AAXZNHDCSA-N
Properties
Molecular formula	C₆₅H₉₂N₁₄O₁₈S₂
Molar mass	1421.64 g mol⁻¹
N (verify) (what is: Y/N?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Edotreotide (USAN, codenamed SMT487, also known as (DOTA⁰-Phe¹-Tyr³)octreotide, or DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.^[1]

It has been the subject of a trial by the National Cancer Institute to determine its effects in young cancer patients (up to 25 years of age) for its ability to locate malignant cancer cells without harming normal cells. Specific cancers being included in the trial include neuroblastoma, childhood brain tumours and gastrointestinal cancer.^[2]

References

^ Martindale, The Extra Pharmacopoeia, 30th ed, p1161.
^ Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Bushnell, D. L.; O'Dorisio, T. M.; O'Dorisio, M. S.; Menda, Y.; Hicks, R. J.; Van Cutsem, E.; Baulieu, J. -L.; Borson-Chazot, F. et al. (2010). "90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide". Journal of Clinical Oncology 28 (10): 1652–1659. doi:10.1200/JCO.2009.22.8585. PMID 20194865. edit

Edotreotide

See also

References